108 related articles for article (PubMed ID: 11310632)
1. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease.
Blandini F; Nappi G; Greenamyre JT
Ann Neurol; 2001 Apr; 49(4):525-9. PubMed ID: 11310632
[TBL] [Abstract][Full Text] [Related]
2. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
4. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
5. The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease.
Blandini F
Funct Neurol; 2001; 16(4 Suppl):99-106. PubMed ID: 11996537
[No Abstract] [Full Text] [Related]
6. Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Turner MS; Gray TS; Mickiewicz AL; Napier TC
Brain Struct Funct; 2008 Sep; 213(1-2):197-213. PubMed ID: 18663473
[TBL] [Abstract][Full Text] [Related]
7. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic nucleus lesions reduce low frequency oscillatory firing of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Tseng KY; Kasanetz F; Kargieman L; Pazo JH; Murer MG; Riquelme LA
Brain Res; 2001 Jun; 904(1):93-103. PubMed ID: 11516415
[TBL] [Abstract][Full Text] [Related]
9. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
10. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
[TBL] [Abstract][Full Text] [Related]
11. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
12. Behavioral responses to injections of muscimol into the subthalamic nucleus: temporal changes after nigrostriatal lesions.
Mehta A; Menalled L; Chesselet MF
Neuroscience; 2005; 131(3):769-78. PubMed ID: 15730880
[TBL] [Abstract][Full Text] [Related]
13. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
14. Unilateral lesion of the pedunculopontine nucleus induces hyperactivity in the subthalamic nucleus and substantia nigra in the rat.
Breit S; Lessmann L; Benazzouz A; Schulz JB
Eur J Neurosci; 2005 Nov; 22(9):2283-94. PubMed ID: 16262666
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.
Vila M; Marin C; Ruberg M; Jimenez A; Raisman-Vozari R; Agid Y; Tolosa E; Hirsch EC
J Neurochem; 1999 Jul; 73(1):344-52. PubMed ID: 10386987
[TBL] [Abstract][Full Text] [Related]
16. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Touchon JC; Moore C; Frederickson J; Meshul CK
Synapse; 2004 Mar; 51(4):287-98. PubMed ID: 14696016
[TBL] [Abstract][Full Text] [Related]
17. MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease.
Allers KA; Bergstrom DA; Ghazi LJ; Kreiss DS; Walters JR
Exp Neurol; 2005 Jan; 191(1):104-18. PubMed ID: 15589517
[TBL] [Abstract][Full Text] [Related]
18. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C
Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469
[TBL] [Abstract][Full Text] [Related]
19. Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease.
Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Exp Neurol; 2008 Aug; 212(2):548-51. PubMed ID: 18508049
[TBL] [Abstract][Full Text] [Related]
20. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat.
Mehta A; Chesselet MF
Exp Neurol; 2005 May; 193(1):110-7. PubMed ID: 15817269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
